Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Logothetis

Showing results (361-370 of 383) with videos related to

Pageof 39
Sort By:
The New England Journal of Medicine|May 27, 2011
Abiraterone and increased survival in metastatic prostate cancerJohann S de Bono, Christopher J Logothetis, Arturo Molina, et al.
European Urology|March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Cancer Discovery|December 25, 2015
Targeting YAP-Dependent MDSC Infiltration Impairs Tumor ProgressionGuocan Wang, Xin Lu, Prasenjit Dey, et al.
The New England Journal of Medicine|December 12, 2012
Abiraterone in metastatic prostate cancer without previous chemotherapyCharles J Ryan, Matthew R Smith, Johann S de Bono, et al.
Cancer Letters|November 30, 2025
KDM4A promotes NEPC progression through regulation of MYC expressionCelia Sze Ling Mak, Ming Zhu, Jie Fu, et al.
Nature Communications|April 5, 2022
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancersOmar Alhalabi, Jianfeng Chen, Yuxue Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 5, 2015
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015S Gillessen, A Omlin, G Attard, et al.
Cancer Discovery|May 13, 2026
A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune ArchitectureKai Yu, Jianfeng Chen, Yu-Yi Chu, et al.
Communications Medicine|May 27, 2026
Polygenic risk score with KLK3 SNP-SNP interaction pairs for predicting prostate cancer aggressivenessHui-Yi Lin, Indrani Sarkar, Harun Mazumder, et al.
Cancers|November 7, 2020
The <i>CHEK2</i> Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common AncestorAndreia Brandão, Paula Paulo, Sofia Maia, et al.
Pageof 39

Showing results (361-370 of 383) with videos related to

Sort By:
Pageof 39
The New England Journal of Medicine|May 27, 2011
Abiraterone and increased survival in metastatic prostate cancerJohann S de Bono, Christopher J Logothetis, Arturo Molina, et al.
European Urology|March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Cancer Discovery|December 25, 2015
Targeting YAP-Dependent MDSC Infiltration Impairs Tumor ProgressionGuocan Wang, Xin Lu, Prasenjit Dey, et al.
The New England Journal of Medicine|December 12, 2012
Abiraterone in metastatic prostate cancer without previous chemotherapyCharles J Ryan, Matthew R Smith, Johann S de Bono, et al.
Cancer Letters|November 30, 2025
KDM4A promotes NEPC progression through regulation of MYC expressionCelia Sze Ling Mak, Ming Zhu, Jie Fu, et al.
Nature Communications|April 5, 2022
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancersOmar Alhalabi, Jianfeng Chen, Yuxue Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 5, 2015
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015S Gillessen, A Omlin, G Attard, et al.
Cancer Discovery|May 13, 2026
A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune ArchitectureKai Yu, Jianfeng Chen, Yu-Yi Chu, et al.
Communications Medicine|May 27, 2026
Polygenic risk score with KLK3 SNP-SNP interaction pairs for predicting prostate cancer aggressivenessHui-Yi Lin, Indrani Sarkar, Harun Mazumder, et al.
Cancers|November 7, 2020
The <i>CHEK2</i> Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common AncestorAndreia Brandão, Paula Paulo, Sofia Maia, et al.
Pageof 39